Cardiovascular disease and 1,5-anhydro-d-glucitol

Area of Science:

• Endocrinology
• Cardiology
• Clinical Biochemistry

Background:

• Hyperglycemia leads to urinary glucose excretion, causing a rapid decrease in serum 1,5-anhydro-d-glucitol (1,5-AG).
• 1,5-AG is recognized as a sensitive indicator of short-term glycemic control, postprandial hyperglycemia, and glucose variability.
• Emerging research highlights the link between glucose fluctuations and cardiovascular disease (CVD).

Purpose of the Study:

• To review the utility and limitations of 1,5-AG as a biomarker for cardiovascular disease (CVD).
• To explore the association between 1,5-AG levels and CVD prevalence and cardiovascular (CV) event prediction.

Main Methods:

• Literature review synthesizing current evidence on 1,5-AG and CVD.
• Analysis of studies investigating the predictive value of 1,5-AG for CV events, particularly in high-risk populations.

Main Results:

• Serum 1,5-AG levels correlate with the prevalence of CVD.
• 1,5-AG demonstrates predictive value for cardiovascular events, with enhanced effectiveness in high-risk populations.
• 1,5-AG serves as a valuable glycometabolic marker, complementing HbA1c by reflecting glucose fluctuations.

Conclusions:

• 1,5-AG shows promise as a marker for CVD risk assessment and prediction.
• Utilizing 1,5-AG may improve patient prognosis and reduce healthcare costs through early detection and better glucose management.
• 1,5-AG offers a complementary perspective to HbA1c for comprehensive glycemic assessment.